A U.S. scientist who co-discovered the virus that causes AIDS will use a $15 million grant to develop a potential vaccine.
Dr. Robert Gallo of the University of Maryland said at a news conference that he will use the five-year grant from the Bill and Melinda Gates Foundation to test a vaccine that could potentially eliminate the virus in already infected cells, The Washington Times said Wednesday.
The vaccine has been tested successfully on monkeys.
The grant is part of the Gates Foundation's Collaboration for AIDS Vaccine Discovery, which started last year with $287 million in grants.
Gallo has a public-private partnership with Wyeth Pharmaceuticals and Profectus BioSciences, a spinoff of the university's Institute of Human Virology, the newspaper said.
Copyright 2007 by United Press International
Related stories:
Scientists Find First Immune Responses to HIV Infection Ineffective
(PhysOrg.com) -- Scientists have identified the very first antibodies to appear in the wake of HIV infection and have concluded that they are virtually impotent in mounting a meaningful defense against the invading virus.
3 share Nobel prize for work on AIDS and cancer
(AP) -- Three European scientists shared the 2008 Nobel Prize in medicine on Monday for separate discoveries of viruses that cause AIDS and cervical cancer, breakthroughs that helped doctors fight the deadly diseases.
A DNA-based vaccine shows promise against avian flu
(PhysOrg.com) -- Though it has fallen from the headlines, a global pandemic caused by bird flu still has the United States’ Centers for Disease Control and Prevention on high alert. Yet, to date, the only vaccines that have proven even semi-effective are produced in chicken eggs, take five to six months to prepare and act against a single variant of the H5N1 virus, which mutates incredibly quickly. Now, new research by scientists in New York and Taiwan has led to a vaccine with the potential to stop most strains of H5N1 flu viruses in their tracks.
NTDs burden in Latin America and the Caribbean may exceed that of HIV/AIDS, TB and malaria
According to a new analysis published September 24th in the open-access journal
PLoS Neglected Tropical Diseases, "The Neglected Tropical Diseases of Latin America and the Caribbean: A Review of Disease Burden and Distribution and a Roadmap for Control And Elimination,", neglected tropical diseases (NTDs) as a group may have surpassed HIV/AIDS, tuberculosis and malaria as the most prevalent infectious diseases in Latin America and the Caribbean. The analysis found that NTDs are the most common infections of approximately 200 million of the poorest people in the region. They include tens of millions of cases of intestinal worm infections, and almost 10 million cases of Chagas disease, as well as schistosomiasis, trachoma, dengue fever, leishmaniasis, lymphatic filariasis (LF), and onchocerciasis.
Behavioral intervention works to reduce risky behavior
In an effort to curb the rising rates of HIV and sexually transmitted infections (STIs) along the Mexico-US border, a binational team of researchers led by the University of California, San Diego School of Medicine have shown that brief but personalized behavioral counseling significantly reduced rates and improved condom use among female sex workers in Tijuana and Ciudad Juarez, Mexico.
Why some primates, but not humans, can live with immunodeficiency viruses and not progress to AIDS
Key differences in immune system signaling and the production of specific immune regulatory molecules may explain why some primates are able to live with an immunodeficiency virus infection without progressing to AIDS-like illness, unlike other primate species, including rhesus macaques and humans, that succumb to disease.
New vaccine to fight multiple vaccine strains
A universal vaccine effective against several strains of influenza has passed its first phase of testing, according to Dr. Christine Turley of the University of Texas at Galveston.
Personalized immunotherapy to fight HIV/AIDS
For a long time, the main obstacle to creating an AIDS vaccine has been the high genetic variability of the HIV virus. Dr. Jean-Pierre Routy and his team from the Research Institute of the McGill University Health Centre (MUHC), in collaboration with Dr. Rafick Sékaly from the Université de Montréal, have overcome this difficulty by designing a personalized immunotherapy for HIV-infected patients. The team's findings were presented on August 5 at the XVII International AIDS Conference in Mexico City.